Karyopharm Therapeutics (NASDAQ: NASDAQ:KPTI) has provided updates on its clinical trials and financial status during the Third Quarter 2024 Financial...
Read moreAviat Networks , Inc. (NASDAQ:AVNW), a global provider of microwave networking solutions, disclosed its financial results for the First Quarter...
Read moreBy Foo Yun Chee BRUSSELS (Reuters) – EU antitrust regulators are investigating whether the fees charged by Visa (NYSE:V) and...
Read moreGogo Inc . (NASDAQ: NASDAQ:GOGO) reported a 3% increase in revenue year-over-year during its Third Quarter earnings call, highlighting the...
Read moreOn October 30, 2024, The Andersons , Inc. (NASDAQ: NASDAQ:ANDE), a diversified company with interests in the grain, ethanol, and...
Read moreStevanato Group (NYSE: STVN), a global provider of drug containment, delivery, and diagnostic solutions, reported a slight revenue increase in...
Read moreInvesting.com — With the U.S. presidential election now behind us and Donald Trump securing a decisive victory, Citi analysts anticipate a...
Read more(Reuters) – Safran (EPA:SAF) has appointed Stephane Cueille as CEO of its Aircraft Engines unit, replacing Jean-Paul Alary effective in...
Read moreEssential Utilities Inc. (NYSE:WTRG) reported a robust financial performance for the third quarter of 2024, with earnings per share (EPS)...
Read moreBy Christoph Steitz FRANKFURT (Reuters) -Potential import tariffs under the U.S. presidency of Donald Trump may benefit BMW (ETR:BMWG), its...
Read moreDisclaimer: WallStreetJedi.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.